In its response to the statement of objections, Aventis states, "As noted in RPB's reply of 1 February, prices were discussed during the annual meetings between RPB and Merck. In particular, the participants would discuss whether to increase the list price, followed by agreement on a minimum percentage increase. However, Merck and RPB did not discuss prices with respect to individual customers. [Merck employee 1] confirmed this in his interview of 19 September 2000"(56).
Recital 86, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002